Unveil Insider Trading for Procter & Gamble, Pfizer, Valeant Pharmaceuticals, Bank of America, Exxon Mobil, and Marvell
HONG KONG, May 28, 2013 /PRNewswire/ -- Insiderslab.com is has released insider trading report for investors who invest in stocks of US: Procter & Gamble (NYSE: PG), Pfizer (NYSE: PFE), Valeant Pharmaceuticals (NYSE: VRX), Bank of America (NYSE: BAC), Exxon Mobil (NYSE: XOM), and Marvell (NASDAQ: MRVL).
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
The Procter & Gamble Company (NYSE: PG): By the end of last trading session, the shares of Procter & Gamble (NYSE: PG) soared US$3.18 (or 4.04%) to US$81.88 with 25.58 million shares exchanged hands, compared to daily average volume of 10.10 million. Insiderslab.com found company insiders sold his/her shares for about US$11.73 million within the last three months. Do you want to know when other C-Level officers selling their shares? Investors may want to find out how Procter & Gamble insiders like CEOs, CFOs and Directors are thinking about the future of the company. Check this insider trade report for PG here.
Read Full Report: http://www.insiderslab.com/PR3/052813A/PG/ProcterGamble.pdf
Pfizer Inc. (NYSE: PFE): By the end of last trading session, Pfizer (NYSE: PFE) shares lost US$0.07 (or 0.24%) to US$29.04 with about 35.08 million shares exchanged hands for the session, compared to its average volume of 37.81 million shares. Insiderslab.com found company CEO, Ian Read, sold his shares at a price of US$29.39 for about US$2.05 million on May 15. The company's other two Executive Vice Presidents, Frank D'Amelio and Amy W. Schulman, followed the same direction to sell his/her shares for about US$4.99 million on the same day. Investors may want to find out how Pfizer insiders like CEOs, CFOs and Directors are thinking about the future of the company.
Read Full Report: http://www.insiderslab.com/PR3/052813A/PFE/Pfizer.pdf
Valeant Pharmaceuticals Intl Inc (NYSE: VRX): By the end of last trading session, Valeant Pharmaceuticals (NYSE: VRX) surged US$9.80 (or 13.12%) to US$84.47 with about 10.38 million shares exchanged hands for the session, compared to its average volume of 1.55 million shares. Insiderslab.com found company Executive Vice President/Company Group Chairman, Laizer D. Kornwasser, purchased his shares at a price of US$70.61, who had about 17.63% return by the end of last trading session. Insiderslab.com believes that it is a clever way to check if insiders like CEOs, CFOs, and Directors in Valeant Pharmaceuticals are starting to buy more company shares. See insider trade report for VRX here.
Read Full Report: http://www.insiderslab.com/PR3/052813A/VRX/ValeantPharmaceuticals.pdf
Today Insiderslab.com also observed abnormal trade volume for the following companies; insiders may involve trading in these companies. It will take some time for insiders to report their trades. Read these reports and add these companies into your Insider Trade Radar.
Bank of America Corp (NYSE: BAC):
Read Full Report: http://www.insiderslab.com/PR3/052813A/BAC/BankofAmerica.pdf
Exxon Mobil Corporation (NYSE: XOM):
Read Full Report: http://www.insiderslab.com/PR3/052813A/XOM/ExxonMobil.pdf
Marvell Technology Group Ltd. (NASDAQ: MRVL):
Read Full Report: http://www.insiderslab.com/PR3/052813A/MRVL/Marvell.pdf
Insider Filing Source Reference: All observations, analysis and reports are based on public information released by the U.S. Securities and Exchange Commission.
Insiderslab.com covers insider trade data in major stock markets in the U.S., Hong Kong, Mainland China, and Singapore. Insiderslab.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.
Please visit insiderslab.com/disclaimers/disclaimers.php for details.
SOURCE Insiderslab.com; Insiders.hk
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.